首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Rapid identification of Streptococcus pneumoniae in blood cultures by using the ImmuLex, Slidex and Wellcogen latex agglutination tests and the BinaxNOW antigen test
【24h】

Rapid identification of Streptococcus pneumoniae in blood cultures by using the ImmuLex, Slidex and Wellcogen latex agglutination tests and the BinaxNOW antigen test

机译:使用ImmuLex,Slidex和Wellcogen乳胶凝集试验和BinaxNOW抗原试验快速鉴定血液培养物中的肺炎链球菌

获取原文
获取原文并翻译 | 示例
       

摘要

Rapid identification of Streptococcus pneumoniae in blood culture (BC) bottles is important for early directed antimicrobial therapy in pneumococcal bacteraemia. We evaluated a new latex agglutination (LA) test on BC bottles, the ImmuLex (TM) S. pneumoniae Omni (Statens Serum Institut, Denmark), and compared the performance with the SlidexA (R) pneumo-Kit (bioM,rieux, France) and the Wellcogen (TM) S. pneumoniae (Remel, UK) LA tests, as well as the BinaxNOWA (R) S. pneumoniae (Alere, USA) antigen test. The four tests were directly applied on 358 positive BC bottles with Gram-positive cocci in pairs or chains and on 15 negative bottles. Valid test results were recorded in all cases for ImmuLex and BinaxNOW and in 88.5 % (330/373) and 94.1 % (351/373) of cases for Slidex and Wellcogen, respectively. Based on bottles positive for S. pneumoniae by conventional methods, the sensitivity of ImmuLex was 99.6 %, similar to the other tests (range, 99.6-100 %). Based on bottles positive for non-pneumococcal pathogens, the specificity of ImmuLex was 82.6 %, in comparison to 97.6 % for Slidex (p < 0.01) and 85.4 % for Wellcogen (p = ns). The BinaxNOW test had a lower specificity (64.1 %) than any LA test (p < 0.01). On BC bottles positive for alpha-haemolytic streptococci, ImmuLex was positive in 12/67 (17.9 %) cases, Slidex in 2/59 (3.4 %) cases, Wellcogen in 11/64 (17.2 %) cases and BinaxNOW in 25/67 (37.3 %) cases. In conclusion, the ImmuLex test provides a valid and sensitive technique for the rapid detection of S. pneumoniae in BC bottles, similar to the other compared methods. However, the specificity was sub-optimal, since the test may cross-react with other Gram-positive bacteria.
机译:在血培养(BC)瓶中快速鉴定肺炎链球菌对于肺炎球菌菌血症的早期定向抗菌治疗非常重要。我们对BC瓶ImmuLex(TM)肺炎链球菌Omni(丹麦Statens Serum Institut,丹麦)的新乳胶凝集(LA)测试进行了评估,并将其与SlidexA(R)气动试剂盒(bioM,rieux,法国)的性能进行了比较。 )和Wellcogen(TM)肺炎链球菌(英国)LA测试,以及BinaxNOWA(R)肺炎链球菌(美国艾勒)抗原测试。这四项测试直接应用于成对或成链的358株革兰氏阳性球菌阳性BC阳性瓶和15阴性瓶。在所有案例中,ImmuLex和BinaxNOW均记录了有效的测试结果,而Slidex和Wellcogen的案例分别记录了88.5%(330/373)和94.1%(351/373)。基于常规方法对肺炎链球菌呈阳性的瓶子,ImmuLex的敏感性为99.6%,与其他测试相似(范围为99.6-100%)。基于对非肺炎球菌病原体呈阳性的瓶子,ImmuLex的特异性为82.6%,而Slidex(p <0.01)和Wellcogen(p = ns)为97.6%(p <0.01)。 BinaxNOW试验的特异性(64.1%)低于任何LA试验(p <0.01)。在BC瓶中,α溶血性链球菌呈阳性,ImmuLex阳性为12/67(17.9%),Slidex为2/59(3.4%),Wellcogen为11/64(17.2%),BinaxNOW为25/67。 (37.3%)的情况。总之,与其他比较方法类似,ImmuLex测试为快速检测BC瓶中的肺炎链球菌提供了一种有效且灵敏的技术。但是,特异性较差,因为该测试可能会与其他革兰氏阳性细菌发生交叉反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号